245 related articles for article (PubMed ID: 1117979)
1. Antiovulatory activity of synthetic corticoids.
Cunningham GR; Caperton EM; Goldzieher JW
J Clin Endocrinol Metab; 1975 Feb; 40(2):265-7. PubMed ID: 1117979
[TBL] [Abstract][Full Text] [Related]
2. Effect of intramuscular triamcinolone acetonide on the human ovulatory cycle.
Carson TE; Daane TA; Lee PA; Tredway DR; Wallin JD
Cutis; 1977 May; 19(5):633-7. PubMed ID: 862425
[TBL] [Abstract][Full Text] [Related]
3. Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat.
Welschen R; Osman P; Dullaart J; de Greef WJ; Uilenbroek JT; de Jong FH
J Endocrinol; 1975 Jan; 64(1):37-47. PubMed ID: 1167896
[TBL] [Abstract][Full Text] [Related]
4. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
5. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
[TBL] [Abstract][Full Text] [Related]
6. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
Carr BR; Parker CR; Madden JD; MacDonald PC; Porter JC
J Clin Endocrinol Metab; 1979 Sep; 49(3):346-9. PubMed ID: 224073
[TBL] [Abstract][Full Text] [Related]
8. Serum follicle-stimulating and luteinizing hormone and progesterone in single and multiple gestations following induction of ovulation.
Fogel M; Rubin BL; Ossowski R
Am J Obstet Gynecol; 1972 Mar; 112(5):629-39. PubMed ID: 5059593
[TBL] [Abstract][Full Text] [Related]
9. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
Croxatto HB; Salvatierra AM; Romero C; Spitz IM
J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
[TBL] [Abstract][Full Text] [Related]
10. Some aspects on pituitary function in human and rat anovulatory cycles.
Makino T; Shiina M; Ohno T; Iizuka R; Tamaoki B
Endocrinol Jpn; 1976 Dec; 23(6):445-9. PubMed ID: 798684
[TBL] [Abstract][Full Text] [Related]
11. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
Cameron ST; Thong KJ; Baird DT
Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of ovulation inhibition by triamcinolone acetonide.
Cunningham GR; Goldzieher JW; de la Pena A; Oliver M
J Clin Endocrinol Metab; 1978 Jan; 46(1):8-14. PubMed ID: 376542
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin, estrogen and progesterone response to long term gonadotropin-releasing hormone infusion at various stages of the menstrual cycle.
Jewelewicz R; Dyrenfurth I; Ferin M; Bogumil J; Vande Wiele RL
J Clin Endocrinol Metab; 1977 Oct; 45(4):662-7. PubMed ID: 334788
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
Nillius SJ; Bergquist C; Wide L
Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
[TBL] [Abstract][Full Text] [Related]
15. The effects of estrogen and progesterone on the functional capacity of the gonadotrophs.
Lasley BL; Wang CF; Yen SS
J Clin Endocrinol Metab; 1975 Nov; 41(5):820-6. PubMed ID: 1102551
[TBL] [Abstract][Full Text] [Related]
16. Temporal relationships between ovulation and defined changes in the concentration of plasma estradiol-17 beta, luteinizing hormone, follicle-stimulating hormone, and progesterone. I. Probit analysis. World Health Organization, Task Force on Methods for the Determination of the Fertile Period, Special Programme of Research, Development and Research Training in Human Reproduction.
Am J Obstet Gynecol; 1980 Oct; 138(4):383-90. PubMed ID: 6775535
[TBL] [Abstract][Full Text] [Related]
17. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
[TBL] [Abstract][Full Text] [Related]
19. Effects of a superactive luteinizing hormone-releasing factor agonist on gonadotropin and ovarian function during the menstrual cycle.
Sheehan KL; Casper RF; Yen SS
Am J Obstet Gynecol; 1979 Nov; 135(6):759-63. PubMed ID: 386801
[TBL] [Abstract][Full Text] [Related]
20. [Blockade of LH and FSH peaks by low doses of exogenous progesterone in the human female (author's transl)].
Netter A; Gorins A; Thomas K; Cohen M; Joubinaux J
Ann Endocrinol (Paris); 1973; 34(4):430-5. PubMed ID: 4779738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
